Epclusa is a fixed-dose combination drug containing velpatasvir and sofosbuvir that can be used to treat hepatitis C (HCV) infection. Velpatasvir is a nucleotide analogue polymerase inhibitor and sofosbuvir is a pan-genotypic NS5A inhibitor. Epclusa contains velpatasvir and sofosbuvir. Velpatasvir works by interfering with a protein called HCV NS5A, which is required by the virus to reproduce itself. Epclusa ingredients initially significantly reduce and then completely stop the production of new copies of the hepatitis C virus. To know about Epclusa cost please visit- https://www.medixocentre.com/epclusa-cost